Genecast Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
16
- Latest Deal Type
-
2ndary - Private
- Investors
-
9
Genecast General Information
Description
Developer of cancer diagnostic technology equipment designed to detect, diagnose, and treat early-stage cancer. The company's technology amplifies only mutated genes while leaving the normal genes intact, and its liquid biopsy method analyzes mutant tumor DNA in the blood, enabling cancer patients to receive effective treatment.
Contact Information
Website
www.igenecast.comCorporate Office
- Number 10009 Garden 5 Techno Hall
- 66, Chungmin-ro, Songpa-gu
- Seoul, 05838
- South Korea
Corporate Office
- Number 10009 Garden 5 Techno Hall
- 66, Chungmin-ro, Songpa-gu
- Seoul, 05838
- South Korea
Genecast Timeline
Genecast Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Secondary Transaction - Private | 01-Apr-2026 | Completed | Generating Revenue | |||
| 5. Later Stage VC | 05-Jun-2024 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series C) | 23-Feb-2023 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series B) | 08-Jun-2020 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A) | 01-May-2018 | $4.85M | $4.85M | Completed | Startup | |
| 1. Seed Round | 01-Dec-2017 | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Genecast Patents
Genecast Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025105837-A1 | Method for large-scale multiplex detection of lung cancer mutant genes using rna and kit for large-scale multiplex detection of lung cancer mutant genes using same | Inactive | 15-Nov-2023 | ||
| WO-2020145734-A1 | Dna polymerase for detecting braf mutations, and kit comprising same | Inactive | 11-Jan-2019 | ||
| WO-2020145715-A1 | Dna polymerase for detecting tert mutation and kit comprising same | Inactive | 11-Jan-2019 | ||
| WO-2020145711-A1 | Dna polymerase for egfr mutation detection and kit comprising same | Inactive | 11-Jan-2019 | ||
| WO-2020145762-A1 | Dna polymerase for jak2 mutation detection, and kit comprising same | Inactive | 11-Jan-2019 | C12Q1/686 |
Genecast Signals
Genecast Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Winvest Venture Capital | Venture Capital | Minority | ||
| Access Bio | Corporation | Minority | ||
| DK&D | Corporation | Minority | ||
| GC Biopharma | Corporation | Minority | ||
| GC Medis | Venture Capital | Minority |
Genecast FAQs
-
When was Genecast founded?
Genecast was founded in 2016.
-
Where is Genecast headquartered?
Genecast is headquartered in Seoul, South Korea.
-
What is the size of Genecast?
Genecast has 16 total employees.
-
What industry is Genecast in?
Genecast’s primary industry is Diagnostic Equipment.
-
Is Genecast a private or public company?
Genecast is a Private company.
-
What is Genecast’s current revenue?
The current revenue for Genecast is .
-
How much funding has Genecast raised over time?
Genecast has raised $23.5M.
-
Who are Genecast’s investors?
Winvest Venture Capital, Access Bio, DK&D, GC Biopharma, and GC Medis are 5 of 9 investors who have invested in Genecast.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process